Team

Dave Guilmette

Chairman of the Board

Dave Guilmette is currently the Chairman of the Board at Master Medical. Previously, he served as the President of Global Employer and Private Healthcare Exchange at Cigna Corporation. At Cigna, he was responsible for leading the growth strategy and overall market execution for the Global Employer segment, which includes global health benefits and national accounts. He also had full leadership responsibility for Cigna's private healthcare exchange business. Before that, he was the President of the National Pharmacy and Product Business. He joined Cigna in February 2010 as President of the National Segment. Prior to that, Guilmette was the Managing Director of the Global Health and Benefits business line at Towers Watson, where he led the growth and profitability of the business and provided insights into healthcare market trends. Guilmette has over 30 years of experience in healthcare and employee benefits programs, focusing on program design, financing, implementation, management, consumer orientation (including consumer-driven health plan design), and healthcare management. Guilmette graduated from the University of Chicago with a Bachelor of Arts in Political Science in 1982

Lulu Vitich

Co-Founder | Investor | Director

Ms. Lulu Vitich is the co-founder, core investor, and board member of the company. With nearly 20 years of extensive experience in high-end manufacturing, global supply chain management, and cross-border business development, Ms. Vitich is a seasoned leader with exceptional strategic vision and execution capabilities in lean production, international compliance systems, and global market access in the medical device industry. Before co-founding the company, she held key management positions in several multinational high-end manufacturing and technology companies, successfully leading multiple large-scale industrial projects in investment, financing, and global business implementation. As one of the founding visionary figures of the company, she has successfully brought in top-tier long-term international capital, including the partner team from the global leading independent asset management giant Baillie Gifford, providing continuous financial support for the company's R&D innovation and capacity expansion. At the company, Ms. Vitich is fully responsible for the global development strategy, top-level capital operations, and core supply chain ecosystem construction, committed to leading the company to become a leading enterprise in the global medical device manufacturing field

Roderick Snell

Investors and Strategic Advisors

Mr. Roderick Snell is a core investor and solid capital support of our company, Baillie Gifford. As a global partner and senior fund manager at Baillie Gifford, a world-leading asset management giant and century-long investment institution, Mr. Snell has over 20 years of outstanding experience in global capital markets and frontier industry investment. He leads and co-manages a flagship investment portfolio exceeding $30 billion, dedicated to discovering and deeply supporting disruptive high-growth companies with global transformative potential. Importantly, Mr. Snell graduated from the University of Edinburgh in the UK, earning a first-class honors degree in Medical Biology. His profound academic background in medicine and forward-looking global capital perspective provide our company with irreplaceable industry insights and continuous capital empowerment in medical device research and development, high-end manufacturing, global supply chain layout, and international strategic expansion

Lorna Kennedy

Investors and Strategic Advisors

Ms. Lorna Kennedy is a core investor and a solid global capital supporter of our company. As the Global Partner and Head of International Business & Financial Institutions at Baillie Gifford, a leading independent asset management giant, Ms. Kennedy has over 25 years of outstanding experience in global asset management, multinational business development, and strategic cooperation with top international financial institutions. She fully leads Baillie Gifford's financial institution relationships and international business growth in key global markets. Ms. Kennedy graduated from the renowned University of St Andrews in the UK. Her top-tier global financial perspective, extensive cross-border capital operation experience, and keen insight into international market expansion provide our company with unparalleled strategic guidance and capital support in the internationalization of medical devices, global commercialization, and the compliant establishment of a multinational supply chain

Virgílio Bento

Board member

Virgílio Bento is the founder and CEO of the digital health unicorn Sword Health and a board member of Master Medical. He is an academic entrepreneur with a strong academic background and technical expertise in artificial intelligence, sensor algorithms, and neuroscience. With over 40 patents in sensor fusion algorithms, artificial intelligence, and neuroplasticity, and more than 40 peer-reviewed scientific papers, he is dedicated to using AI to address the traditional physical therapy challenges of "high costs and limited coverage." He led the company to develop the world's first AI medical therapist, Phoenix, which helps patients avoid unnecessary medical expenses through AI. By 2024, he had led the company through multiple rounds of financing, bringing Sword Health's valuation to $3 billion, and was named one of the "100 Most Influential People in Healthcare" by Modern Healthcare

Anna Victorovna Ivanova

Investor | Director

Anna Viktorovna Ivanova is an accomplished medical technology commercialization strategist and private equity venture advisor with over 15 years of extensive experience in infrastructure management, cross-border M&A due diligence, and high-risk regulatory governance. Prior to joining Master Medical as a core founding member, she served as a senior partner at several leading independent business consulting firms and a venture partner at several private medical technology funds, accumulating over a decade of experience. Anna primarily works within highly confidential, NDA-protected transaction frameworks, focusing on driving the operational readiness and post-acquisition stability of pre-IPO digital health platforms and medical device startups. Her core expertise lies in translating clinical prototypes into industrial-scale production operations through robust supply chain audits, managing $250 million in capital expenditure (CapEx) tracking, and expertise in supplier equipment leasing compliance. Her tenure is marked by her unique ability to navigate unpredictable regulatory environments, develop standardized macro-cost control measures, and seamlessly integrate multidisciplinary teams of data scientists, automation engineers, and healthcare executives to optimize enterprise-level metrics and accelerate time-to-market